BiotechTube
Home/Solid Biosciences/Ty Howton
TH

Ty Howton

Chief Operating Officer

Solid Biosciences

Therapeutic Areas

Neuromuscular DiseasesCardiac Diseases

Solid Biosciences Pipeline

DrugIndicationPhase
SGT-003Duchenne Muscular Dystrophy (Duchenne)Phase I/II
SGT-212Friedreich’s ataxia (FA)Phase I/II
SGT-501Catecholaminergic polymorphic ventricular tachycardia (CPVT)Phase I/II
SGT-601TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseasesPreclinical

Leadership Team at Solid Biosciences

BC
Bo Cumbo
President and CEO
KT
Kevin Tan
Chief Financial Officer
JH
Jessie Hanrahan, Ph.D.
Chief Regulatory & Preclinical Operations Officer
DG
Dr. Gabriel Brooks, M.D.
Chief Medical Officer
PH
Paul Herzich
Chief Technology Officer
SK
Shuli Kulak, M.D.
Head of Corporate Strategy and Business Development
View full Solid Biosciences profile